ABOUT US
WHAT WE DO
INVESTORS
CONTACT US
Back
ABOUT PCI BIOTECH
BOARD OF DIRECTORS
MANAGEMENT
SCIENTIFIC ADVISORY COMMITTEE
COMPANY PRESENTATION
Back
TECHNOLOGY
SCIENTIFIC PUBLICATIONS & PRESENTATIONS
PIPELINE
PARTNERING
Back
INVESTORS
NEWS
REPORTS AND PRESENTATIONS
SHARE INFORMATION
GENERAL MEETING INFORMATION
FINANCIAL CALENDAR
CORPORATE GOVERNANCE AND CSR
NOMINATION COMMITTEE
ABOUT US
ABOUT PCI BIOTECH
BOARD OF DIRECTORS
MANAGEMENT
SCIENTIFIC ADVISORY COMMITTEE
COMPANY PRESENTATION
WHAT WE DO
TECHNOLOGY
SCIENTIFIC PUBLICATIONS & PRESENTATIONS
PIPELINE
PARTNERING
INVESTORS
INVESTORS
NEWS
REPORTS AND PRESENTATIONS
SHARE INFORMATION
GENERAL MEETING INFORMATION
FINANCIAL CALENDAR
CORPORATE GOVERNANCE AND CSR
NOMINATION COMMITTEE
CONTACT US
fima
V
ACC
Enhanced T-cell response for vaccination
fima
NA
C
Nucleic acid therapeutics delivery
LATEST NEWS
NEWS
Feb 14, 2024
PCI Biotech second half 2023 interim report
Feb 14, 2024
Feb 14, 2024
Feb 12, 2024
Invitation to second half interim 2023 results presentation
Feb 12, 2024
Feb 12, 2024
Oct 13, 2023
PCI Biotech initiates field testing of its proprietary technology for gene therapy manufacturing
Oct 13, 2023
Oct 13, 2023
<- Older entries
Subscribe to our newsletter
Sign up with your email address to receive news and updates.
First Name
Last Name
Email Address
Sign Up
Privacy Policy
Thank you!
